Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 3/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 4/20 | 0.32 |
| ▸ | CTSB | P07858 | 3/20 | 0.32 |
| ▸ | CTSS | P25774 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31252248 | 0.91 | SMN1; SMN2 (0.35) | AKT1NFKB1NFKB2RELAMEN1 | |
| SCHEMBL32687873 | 0.83 | NPSR1 (0.33) | AKT1 | |
| SCHEMBL25232223 | 0.82 | NPSR1 (0.33) | AKT1CA12CA14 | |
| SCHEMBL26690201 | 0.79 | NFKB1 (0.37) | NFKB1NFKB2RELAMEN1KMT2A | |
| SCHEMBL8430714 | 0.79 | CYP3A4 (0.49) | AKT1MEN1KMT2AALDH1A1CYP2C9 | |
| SCHEMBL1771498 | 0.78 | NFKB1 (0.36) | NFKB1NFKB2RELAMEN1KMT2A | |
| SCHEMBL30733418 | 0.78 | AKT1 (0.35) | AKT1 | |
| SCHEMBL32687916 | 0.76 | NFKB1 (0.35) | NFKB1NFKB2RELAMEN1KMT2A | |
| SCHEMBL13435746 | 0.75 | NFKB1 (0.40) | NFKB1NFKB2RELAMEN1KMT2A | |
| SCHEMBL2271664 | 0.73 | AKT1 (0.36) | AKT1NFKB1NFKB2RELACTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720072-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260078133-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2026-03-19 | — | — | US | disclosed |
| WO-2024249299-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2024-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078133-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | AKT1 39/4885NFKB1 2455/4885NFKB2 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.